Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.50 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8310570 | 0.90 | ERCC1 (0.56) | ERCC1ERCC4MASP2CARM1PRMT6 | |
| SCHEMBL20428059 | 0.88 | ERCC1 (0.57) | ERCC1ERCC4CARM1PRMT6LMNA | |
| SCHEMBL18251700 | 0.82 | ERCC1 (0.55) | ERCC1ERCC4CARM1PRMT6CYP2D6 | |
| SCHEMBL18251695 | 0.81 | ERCC1 (0.50) | ERCC1ERCC4CARM1PRMT6LMNA | |
| SCHEMBL12864453 | 0.77 | ERCC1 (0.58) | ERCC1ERCC4MASP2LMNAMEN1 | |
| SCHEMBL21565748 | 0.77 | TACR1 (0.53) | ERCC1ERCC4TACR1 | |
| SCHEMBL8310068 | 0.76 | MEN1 (0.63) | ERCC1ERCC4CARM1PRMT6LMNA | |
| SCHEMBL28276130 | 0.76 | CARM1 (0.45) | ERCC1ERCC4CARM1PRMT6LMNA | |
| SCHEMBL12757442 | 0.75 | ERCC1 (0.59) | ERCC1ERCC4CYP2D6CYP2C19NPC1 | |
| SCHEMBL5025058 | 0.75 | TACR1 (0.50) | ERCC1ERCC4MASP2CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656962-B2 | Ring-contracted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | OPRM1, OPRL1, OPRK1 | ERCC1 4732/4885ERCC4 4747/4885MASP2 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.